Bradford J Shafer
CIK 1302448 · EVP, Gen. Counsel, Secretary · last filed 2021-08-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
THRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) Delisted | EVP, Gen. Counsel, Secretary | 277,831 | $17.03 | $4.73M | -$4.06M | 43 | 2021-08-24 |
| Innoviva, Inc. (THRX) Delisted | Sr VP, Gen. Counsel, Secretary | 445,763 | $4.06 | $1.81M | -$6.98M | 44 | 2014-08-22 |
Recent Filings · Page 4 of 9
87 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-11-22 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −4,008 | -$128.1K | EDGAR |
| 2016-08-22 | Theravance Biopharma, Inc. (TBPH) Delisted | Mixed | −53,130 | -$1.46M | EDGAR |
| 2016-05-24 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −4,008 | -$82.4K | EDGAR |
| 2016-03-17 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +115,000 | $0 | EDGAR |
| 2016-02-23 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −18,920 | -$296.1K | EDGAR |
| 2015-11-24 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −934 | -$16.0K | EDGAR |
| 2015-08-24 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −934 | -$12.1K | EDGAR |
| 2015-06-04 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −7,360 | -$101.8K | EDGAR |
| 2015-05-22 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −673 | -$9.6K | EDGAR |
| 2015-02-24 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −674 | -$13.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.